JP2005528398A5 - - Google Patents

Download PDF

Info

Publication number
JP2005528398A5
JP2005528398A5 JP2003584049A JP2003584049A JP2005528398A5 JP 2005528398 A5 JP2005528398 A5 JP 2005528398A5 JP 2003584049 A JP2003584049 A JP 2003584049A JP 2003584049 A JP2003584049 A JP 2003584049A JP 2005528398 A5 JP2005528398 A5 JP 2005528398A5
Authority
JP
Japan
Prior art keywords
per
blood
antidiabetic
average
recorded
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003584049A
Other languages
English (en)
Japanese (ja)
Other versions
JP4309769B2 (ja
JP2005528398A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IN2002/000105 external-priority patent/WO2003087093A1/en
Publication of JP2005528398A publication Critical patent/JP2005528398A/ja
Publication of JP2005528398A5 publication Critical patent/JP2005528398A5/ja
Application granted granted Critical
Publication of JP4309769B2 publication Critical patent/JP4309769B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003584049A 2002-04-08 2002-04-08 新規なグルコピラノサイド、その分離方法、それを含む薬物及びその使用方法 Expired - Fee Related JP4309769B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2002/000105 WO2003087093A1 (en) 2002-04-08 2002-04-08 Novel glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof

Publications (3)

Publication Number Publication Date
JP2005528398A JP2005528398A (ja) 2005-09-22
JP2005528398A5 true JP2005528398A5 (https=) 2009-05-07
JP4309769B2 JP4309769B2 (ja) 2009-08-05

Family

ID=29227416

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003584049A Expired - Fee Related JP4309769B2 (ja) 2002-04-08 2002-04-08 新規なグルコピラノサイド、その分離方法、それを含む薬物及びその使用方法

Country Status (7)

Country Link
EP (1) EP1495019B1 (https=)
JP (1) JP4309769B2 (https=)
CN (1) CN1280290C (https=)
AT (1) ATE399778T1 (https=)
AU (1) AU2002246317A1 (https=)
DE (1) DE60227421D1 (https=)
WO (1) WO2003087093A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2363941T3 (es) 2003-03-14 2011-08-19 Astellas Pharma Inc. Derivados de c-glucósido para el tratamiento de diabetes.
EP1679965A4 (en) 2003-08-01 2009-05-27 Janssen Pharmaceutica Nv SUBSTITUTED ANELLIERED HETEROCYCLIC C-GLYCOSIDES
WO2005012242A2 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica Nv Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides
TW200526678A (en) 2003-08-01 2005-08-16 Janssen Pharmaceutica Nv Substituted indole-O-glucosides
WO2005011592A2 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indazole-o-glucosides
BRPI0508259A (pt) * 2004-03-04 2007-07-31 Kissei Pharmaceutical derivado heterocìclico fundido, composição medicinal contendo o mesmo, e uso medicinal do mesmo
PL381247A1 (pl) * 2004-03-04 2007-05-14 Kissei Pharmaceutical Co., Ltd. Skondensowana pochodna heterocykliczna, zawierająca ją kompozycja lecznicza, oraz jej zastosowanie lecznicze
WO2008075736A1 (ja) 2006-12-21 2008-06-26 Astellas Pharma Inc. C-グリコシド誘導体の製造方法及びその合成中間体
TW201623321A (zh) 2014-05-13 2016-07-01 韓美藥品股份有限公司 雙環衍生物及包含其之藥學組成物
CN106674311B (zh) * 2016-12-27 2019-02-05 西安交通大学 一种苯并呋喃苷类化合物及其制备方法和应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6627611B2 (en) * 2000-02-02 2003-09-30 Kotobuki Pharmaceutical Co Ltd C-glycosides and preparation of thereof as antidiabetic agents

Similar Documents

Publication Publication Date Title
JP2003503454A5 (https=)
JP2005518413A5 (https=)
WO2003037864A1 (en) Indole compound and medicinal use thereof
JP2006526031A5 (https=)
JP2007514005A5 (https=)
NO2017047I1 (no) Tofacitinib, evt. i form av et farmasøytisk akseptabelt salt, inkludert citratsalt
JP2002511411A5 (https=)
JP2003520232A5 (https=)
EP1498411A4 (en) DICETOHYDRAZINE DERIVATIVE COMPOUNDS AND MEDICAMENTS CONTAINING THESE COMPOUNDS AS ACTIVE INGREDIENTS
EP2298416A3 (en) Sustained-release tramadol formulations with 24-hour clinical efficacy
JP2007501251A5 (https=)
JP2005528398A5 (https=)
EP1803710A4 (en) CONDENSED PYRIMIDINE DERIVATIVE CONTAINING NON-AROMATIC CYCLE
JP2008513510A5 (https=)
JP2007510699A5 (https=)
JP2003526626A5 (https=)
EP2072049A3 (en) Solid valsartan pharmaceutical compositions
JP2008516004A5 (https=)
JP2004532828A5 (https=)
JP2005526053A5 (https=)
CA2489140A1 (en) Dosage form containing pantoprazole as active ingredient
IL162853A0 (en) The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus
JP2004517961A5 (https=)
JP2004026743A5 (https=)
JP2007507472A5 (https=)